Oaktree Acquisition Corp. III Life Sciences (OACC)
NASDAQ: OACC · Real-Time Price · USD
10.47
+0.02 (0.18%)
Aug 15, 2025, 4:00 PM - Market closed
Company Description
Oaktree Acquisition Corp. III Life Sciences does not have significant operations.
The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe.
The company was incorporated in 2024 and is based in Los Angeles, California.
Oaktree Acquisition Corp. III Life Sciences
| Country | United States |
| Founded | 2024 |
| IPO Date | Oct 24, 2024 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Zaid Pardesi |
Contact Details
Address: 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 United States | |
| Phone | 213 830 6300 |
| Website | oaktreeacquisitioncorp.com |
Stock Details
| Ticker Symbol | OACC |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002029769 |
| ISIN Number | KYG6717R1048 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Zaid Pardesi | Chief Executive Officer and Director |
| Thomas Sweeney | Chief Financial Officer, Principal Accounting and Financial Officer |
| Mathew M. Pendo | Chief Operation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 15, 2025 | SCHEDULE 13G/A | Filing |
| Jun 6, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 9, 2025 | SCHEDULE 13G | Filing |
| Mar 27, 2025 | 10-K | Annual Report |